Cidara Therapeutics (CDTX) Price & Analysis

Compare

777 Followers

CDTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$10.14 - $69.36

Previous CloseN/A

Volume155.01K

Average Volume (3M)509.31K

Market Cap

$1.70B

Enterprise Value$242.73M

Total Cash (Recent Filing)$510.57M

Total Debt (Recent Filing)$2.33M

Price to Earnings (P/E)―

Beta2.50

Next Earnings

Nov 06, 2025

EPS Estimate

-1.64

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.65

Shares Outstanding25,358,051

10 Day Avg. Volume531,057

30 Day Avg. Volume509,313

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.14

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-2.67

Enterprise Value/Ebitda-1.96

Forecast

1Y Price Target

$74.00

Price Target Upside13.17% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessCidara announced positive topline results from its Phase 2b trial, NAVIGATE, evaluating CD388.

Financial HealthThe company ended the quarter with $516.9 million in cash, which is inclusive of a recent financing with gross proceeds of $402 million.

Regulatory ProgressThe upcoming end-of-Phase 2 meeting with the FDA is anticipated to provide the green light for initiating the Phase 3 pivotal program.

Bears Say

Market DependenceThe readout will be a binary catalyst for the stock and is biased toward a positive outcome.

Risk PerceptionA statistically significant risk reduction in the 45-55% range would provide significant upside to current levels or CDTX shares re-rating in the $31-36 range.

Cidara Therapeutics News

Cidara Therapeutics price target raised to $74 from $54 at Needham

Needham raised the firm’s price target on Cidara Therapeutics (CDTX) to $74 from $54 and keeps a Buy...

21d ago

CDTX

Cidara Therapeutics price target raised to $70 from $69 at Guggenheim

Guggenheim raised the firm’s price target on Cidara Therapeutics (CDTX) to $70 from $69 and keeps a Buy...

21d ago

CDTX

Cidara Therapeutics price target raised to $74 from $53 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Cidara Therapeutics (CDTX) to $74 from $53 and keeps a...

21d ago

CDTX

Cidara Therapeutics price target raised to $66 from $59 at Citizens JMP

Citizens JMP analyst Roy Buchanan raised the firm’s price target on Cidara Therapeutics (CDTX) to $66 from $59...

21d ago

CDTX

Cidara Therapeutics reports Q2 EPS ($1.65), consensus ($1.82)

“The highly compelling results of our Phase 2b NAVIGATE trial for CD388 and subsequent financing puts us in...

21d ago

CDTX

Cidara Therapeutics price target raised to $115 from $75 at RBC Capital

RBC Capital raised the firm’s price target on Cidara Therapeutics (CDTX) to $115 from $75 and keeps an...

22d ago

CDTX

Cidara Therapeutics: Promising Trials Amidst Financial Challenges

Cidara Therapeutics Inc. (($CDTX)) has held its Q2 earnings call. Read on for the main highlights of the...

16d ago

CDTX

Cidara Therapeutics Reports Positive Trial Results and Financial Growth

Cidara Therapeutics Inc. ( ($CDTX) ) has released its Q2 earnings. Here is a breakdown of the information...

21d ago

CDTX

Cidara Therapeutics price target raised to $69 from $68 at Guggenheim

Guggenheim raised the firm’s price target on Cidara Therapeutics (CDTX) to $69 from $68 and keeps a Buy...

2M ago

CDTX

Cidara Therapeutics announces inclusion in Russell 2000, 3000 Indexes

Cidara Therapeutics (CDTX) announced its addition to the Russell 2000 and Russell 3000 Indexes. Published first on TheFly...

2M ago

CDTX

Cidara Therapeutics Announces $350 Million Stock Offering

Cidara Therapeutics ( ($CDTX) ) has issued an update. On June 24, 2025, Cidara Therapeutics announced an agreement...

2M ago

CDTX

Cidara Therapeutics 7.95M share Secondary priced at $44.00

The deal size was increased to $350M from $250M and priced below last closing price of $46.84. JPMorgan,...

2M ago

CDTX

Cidara Therapeutics Suspends ATM Prospectus with Jefferies

Cidara Therapeutics ( ($CDTX) ) has issued an update. On June 24, 2025, Cidara Therapeutics announced the suspension...

2M ago

CDTX

Cidara Therapeutics price target raised to $68 from $50 at Guggenheim

Guggenheim raised the firm’s price target on Cidara Therapeutics (CDTX) to $68 from $50 and keeps a Buy...

2M ago

CDTX

CDTX FAQ

What was Cidara Therapeutics’s price range in the past 12 months?

Cidara Therapeutics lowest stock price was $10.14 and its highest was $69.36 in the past 12 months.

What is Cidara Therapeutics’s market cap?

Cidara Therapeutics’s market cap is $1.70B.

When is Cidara Therapeutics’s upcoming earnings report date?

Cidara Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.

How were Cidara Therapeutics’s earnings last quarter?

Cidara Therapeutics released its earnings results on Aug 07, 2025. The company reported -$1.65 earnings per share for the quarter, beating the consensus estimate of -$1.94 by $0.29.

Is Cidara Therapeutics overvalued?

According to Wall Street analysts Cidara Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cidara Therapeutics pay dividends?

Cidara Therapeutics does not currently pay dividends.

What is Cidara Therapeutics’s EPS estimate?

Cidara Therapeutics’s EPS estimate is -1.64.

How many shares outstanding does Cidara Therapeutics have?

Cidara Therapeutics has 25,358,051 shares outstanding.

What happened to Cidara Therapeutics’s price movement after its last earnings report?

Cidara Therapeutics reported an EPS of -$1.65 in its last earnings report, beating expectations of -$1.94. Following the earnings report the stock price went up 0.437%.

Which hedge fund is a major shareholder of Cidara Therapeutics?

Currently, no hedge funds are holding shares in CDTX

Cidara Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-37.05%

Trailing 12-Months

Asset Growth

208.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cidara Therapeutics

Cidara Therapeutics (CDTX) is a biotechnology company focused on the development of novel therapeutics for the treatment of fungal infections and other serious diseases. The company operates primarily in the biotechnology sector, leveraging its innovative platform to design and develop new medicines that address unmet medical needs. Cidara's core products include its lead candidate, rezafungin, an antifungal agent aimed at treating invasive fungal infections, and its Cloudbreak platform, which is designed for the development of combination therapies.

Cidara Therapeutics (CDTX) Earnings & Revenues

Historic Earnings Reports

CDTX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong positive outlook for Cidara Therapeutics due to successful clinical trial results, significant financial backing, and advancing regulatory discussions. However, challenges remain due to the company's non-revenue generating status and potential delays in Phase III study commencement.View all CDTX earnings summaries

CDTX Stock 12 Month Forecast

Average Price Target

$74.00

▲(13.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","116":"$116","35.75":"$35.8","62.5":"$62.5","89.25":"$89.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$74.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,35.75,62.5,89.25,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.9,66.9076923076923,70.91538461538461,74.92307692307692,78.93076923076923,82.93846153846154,86.94615384615385,90.95384615384614,94.96153846153845,98.96923076923076,102.97692307692307,106.98461538461538,110.99230769230769,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.9,63.753846153846155,64.6076923076923,65.46153846153847,66.31538461538462,67.16923076923077,68.02307692307693,68.87692307692308,69.73076923076923,70.58461538461539,71.43846153846154,72.29230769230769,73.14615384615385,{"y":74,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.9,61.52307692307692,60.146153846153844,58.76923076923077,57.39230769230769,56.01538461538461,54.63846153846154,53.261538461538464,51.88461538461539,50.50769230769231,49.13076923076923,47.753846153846155,46.37692307692308,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.81,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.89,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.89,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.61,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.88,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >